CTIS2023-507389-15-00进行中（未招募）1 期
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma - GO40558
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically confirmed metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage IIIC or IIID) cutaneous, acral, or mucosal melanoma, as defined by the AJCC v8.0, ECOG Performance Status of 0 or 1, Life expectancy = 12 weeks, Adequate hematologic and end-organ function, Measurable disease per RECIST v1.1, Naive to prior systemic anti-cancer therapy for advanced melanoma, with the exceptions as specified in the protocol
排除标准
- •Ocular/uveal melanoma, Known clinically significant liver disease, Previous splenectomy, Any anti-cancer therapy with the exceptions as specified in the protocol, History of autoimmune disease, Positive test for HIV infection
研究者
相似试验
招募中
1 期
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal AdenocarcinomaPancreatic ductal adenocarcinomaMedDRA version: 21.1Level: LLTClassification code: 10051971Term: Pancreatic adenocarcinoma Class: 10029104CTIS2022-502404-73-00Genentech Inc.566
进行中（未招募）
不适用
Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancerEUCTR2009-012439-14-CZAstellas Pharma Global Development, Inc. (APGD)100
进行中（未招募）
1 期
Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancerAdenocarcinoma of the breast that is HER2 negative.MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012439-14-BEAstellas Pharma Global Development, Inc. (APGD)100
进行中（未招募）
不适用
Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancerEUCTR2009-012439-14-DEAstellas Pharma Global Development, Inc. (APGD)100
进行中（未招募）
不适用
Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancerEUCTR2009-012439-14-IEAstellas Pharma Global Development, Inc. (APGD)100